Differential effect of cholera toxin on CD45RA+ and CD45RO+ T cells: specific inhibition of cytokine production but not proliferation of human naive T cells.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Differential effect of cholera toxin on CD45RA+ and CD45RO+ T cells: specific inhibition of cytokine production but not proliferation of human naive T cells.

Clin Exp Immunol. 2000 Aug;121(2):283-8. Unique Identifier : AIDSLINE MED/20389932
Eriksson K; Nordstrom I; Czerkinsky C; Holmgren J; Department of Medical Microbiology and Immunology, Goteborg; University, Goteborg, Sweden and INSERM 4 U 364, Nice, France.; kristina.eriksson@microbio.gu.se

Abstract: We have studied how cholera toxin (CT) and its non-toxic cell-binding B-subunit (CTB) affect the activation of pure human T cells in an anti-CD3-driven system. CT, as opposed to CTB, strongly suppressed the proliferative responses as well as cytokine production in CD4+ and CD8+ T cells. CT however, had a differential effect on naive and activated/memory T cell subsets. Costimulation through exogenous IL-2 or through CD28 cross-linking rescued the proliferation of CT-treated naive CD45RA+ T cells, but not of activated/memory CD45RO+ cells. IL-2 production and IL-2 receptor expression were markedly reduced by CT in all T cell fractions, i.e. also in CD45RA+ cells which had maintained proliferative responses. However, the proliferative responses of CT-treated CD45RA+ T cells were IL-2-dependent, as shown by blocking experiments using anti-IL-2 antibodies. These results indicate (i) that CTB has no cytostatic effect on human T cells, (ii) that CT affects proliferation and cytokine production by two different signal pathways, and (iii) that CT might interact with a signal pathway generated through or influenced by CD45.

Keywords: JOURNAL ARTICLE Adult Antigens, CD45/*ANALYSIS/PHYSIOLOGY Cell Division/DRUG EFFECTS Cholera Toxin/*PHARMACOLOGY Comparative Study Cyclic AMP/PHYSIOLOGY CD4-Positive T-Lymphocytes/DRUG EFFECTS/IMMUNOLOGY/SECRETION CD8-Positive T-Lymphocytes/DRUG EFFECTS/IMMUNOLOGY/SECRETION Forskolin/PHARMACOLOGY Human Interferon Type II/SECRETION Interleukin-10/SECRETION Interleukin-2/ANALYSIS Interleukin-4/SECRETION Lymphocyte Transformation/DRUG EFFECTS/*PHYSIOLOGY Lymphokines/*SECRETION Receptors, Antigen, T-Cell/IMMUNOLOGY Recombinant Proteins/PHARMACOLOGY Second Messenger Systems Signal Transduction/PHYSIOLOGY Support, Non-U.S. Gov't T-Lymphocyte Subsets/*DRUG EFFECTS/IMMUNOLOGY/SECRETION Th1 Cells/DRUG EFFECTS/IMMUNOLOGY/SECRETION Th2 Cells/DRUG EFFECTS/IMMUNOLOGY/SECRETION

001130
A00B1162

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .